

Massachusetts Neuroscience Consortium

Full Proposal Application Round 2

RFP Objective: Solicit applications from academic and research organizations interested in identifying and validating targets for neurodegenerative and neuroinflammatory diseases (such as ALS, AD, Huntington's, MS, PD), neuropathic pain and treatment-resistant depression. Proposed research must be translational (rather than exploratory) and anchored in recognized human disease genetics and pathophysiology, or within pathways of known relevance to human disease.

Full Proposal Responses: must be received by **Noon on September 8, 2014**

The Massachusetts Neuroscience Consortium Overview: The Massachusetts Neuroscience Consortium (Consortium) is designed to accelerate pre-clinical research available to the pharmaceutical industry, introduce academic researchers to the challenges of targeted research, and facilitate industry-academic partnerships. The Consortium is comprised of pharmaceutical companies that recognize the value of leveraging the rich Massachusetts environment in the field of neuroscience. Through engagement with researchers representing all major fields of neurobiology and neurology, Consortium Members are seeking an opportunity to advance our collective understanding and treatment of neurological diseases.

AbbVie, Biogen Idec, EMD Serono, Janssen Research and Development, Merck, and Sunovion (Consortium Members) are collaborating with the MLSC to fund the identification and validation of novel targets for the symptomatic treatment and modification of chronic and debilitating neurological diseases. Each of the Consortium Members has contributed to the total available project funding of \$1,500,000. All funding decisions will be made exclusively by Consortium Members.

Full Proposal Application Process: Applicants invited to submit Full Proposals are required to submit their proposal in .pdf format by **Noon on September 8, 2014** to the Massachusetts Life Sciences Center at neuroscience@masslifesciences.com.

Consortium Members will review all Full Proposal applications and potentially invite applicants to present and discuss their application. Award decisions are anticipated to be made in October.

Founding Members:

abbvie

biogen idec

EMD
SERONO

janssen

MERCK

SUNOVION

Managed By:

MASSACHUSETTS
LIFE SCIENCES
CENTER

Full Proposal Application:

Applicants invited to submit Full Proposals¹ are required to provide the following:

- Detailed description of the proposed project, including the following separate sections (up to 5 pages)
 1. Background
 2. Specific aims
 3. Details of the proposed project
 4. Preliminary data
 5. Explicit explanation of its relevance to human disease
- Specific objectives and outcomes of the research including what questions will be answered if the project is successful and potential opportunities to collaborate with the industry sponsors listed above (1-2 pages)
- Description of how the proposed project will leverage existing resources and/or expertise in the applicant's lab (1 page)
- Milestones and a detailed timeline for the work (1 page) with start and end dates (assume that Grant Agreements will be executed in November of 2014) including:
 1. Goal(s) of the proposed work
 2. Timeline for the proposed work
 3. Estimate of funding needed per milestone
 4. Quantifiable measures of success
 5. Brief rationale for research approach (choice of models, parameters, quantitative values, etc.) and how it relates to go/no go milestones. This section should be brief (3-4 sentences) or reference other sections of the proposal that provide more detail.
- Detailed budget for the project (use attached budget template)
- Documentation that your institution has approved the budget and terms of the Grant Agreement (available at <http://www.masslifesciences.com/programs/neurosci>)
- The biosketch of researchers who will be performing the work (these should follow the NIH format and not exceed 4 pages per person – such biosketches will not be included in the page limit)
- A list of references, such as published papers, abstracts, patent applications or other relevant material. Applicants may provide links to such materials, if available.

¹ Application text must be in Arial or Times New Roman font and can be no smaller than 12-point type. Figures, charts, tables, figure legends, and footnotes must be incorporated into the text and must be readily legible. Single-spacing is allowed. Margins, in all directions, must be at least 0.5 inches.